« Back to Record
Citation APA

Lutz, M. B., Van Cutsem, E., Wagener, T., Van Laethem, J.-L., Vanhoefer, U., Wils, J., Gamelin, E., Koehne, C. H., Arnaud, J.-P., Mitry, E., Husseini, F., Reichardt, P., El-Serafi, M., Etienne, P.-L., Lingenfelser, T., Praet, M., Genicot, B., Debois, M., Nordlinger, B., Ducreux, M., & European Organisation for Research and Treatment of Cancer Gastrointestinal Group, (2005). Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Journal of clinical oncology, 23(36), 9250-9256. doi:10.1200/JCO.2005.02.1980


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/111456

Lutz, M. B., Van Cutsem, E., Wagener, T., Van Laethem, J.-L., Vanhoefer, U., Wils, J., Gamelin, E., Koehne, C. H., Arnaud, J.-P., Mitry, E., Husseini, F., Reichardt, P., El-Serafi, M., Etienne, P.-L., Lingenfelser, T., Praet, M., Genicot, B., Debois, M., Nordlinger, B., Ducreux, M., & European Organisation for Research and Treatment of Cancer Gastrointestinal Group, (2005). Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Journal of clinical oncology, 23(36), 9250-9256. doi:10.1200/JCO.2005.02.1980